Description
Introduction of Miqnaf 400mg Tablet:
Miqnaf 400mg Tablet is a novel lactone-ketolide antibiotic containing Nafithromycin. It’s approved in India for treating community-acquired bacterial pneumonia (CABP) in adults, including cases caused by multi-drug resistant bacteria. This medicine is structurally related to macrolides but engineered to overcome the resistance seen with older drugs in this class.
It should be taken exactly as prescribed by your doctor, once daily, for the full three-day course — even if symptoms start to improve before treatment ends.
Uses:
- Community-acquired bacterial pneumonia (CABP) in adults
Benefits:
1. Effective against drug-resistant bacteria
This medicine kills macrolide-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae, and remains active against atypical pathogens like Mycoplasma, Chlamydia, and Legionella. It’s especially useful in areas where resistance to azithromycin or amoxicillin is rising.
2. Ultra-short course treatment
It’s taken once daily for just three days, shortening the treatment duration while maintaining high efficacy. This helps improve patient compliance and reduces the risk of antibiotic misuse.
3. High lung tissue penetration
The tablet delivers concentrated action directly at the site of infection in the lungs, supporting better outcomes in treating CABP.
4. Well-tolerated and convenient
Compared to older antibiotics, it causes fewer gastrointestinal and systemic side effects. As an oral tablet, it also avoids the need for hospital-based IV treatment in most cases.
Mechanism of Action:
Miqnaf 400mg Tablet works by binding to bacterial ribosomes, specifically the 50S subunit, which bacteria need for protein synthesis. It has a dual binding mechanism, attaching to both domain II and domain V of the 23S rRNA within the 50S ribosomal unit. This blocks bacterial protein formation, leading to inhibited growth and eventual bacterial death.
Its unique structure allows it to overcome resistance mechanisms that affect older macrolides like azithromycin or erythromycin, showing strong binding affinity even in bacteria with ribosomal mutations or efflux pumps — making it effective against multi-drug resistant organisms.
Who Manufactures It:
Miqnaf 400mg Tablet is manufactured by Wockhardt Bio AG, supplied as a strip, and should be stored between 20°C and 25°C.
Reviews
There are no reviews yet.